|
|
|
|
|
|
|
 
|
Pancreas Cancer News and Archives | |
 |
For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer | |
|
SuperGen Announces Orathecin(TM) as New 'Brand Name' for Rubitecan DUBLIN, California, March 7, 2002 SuperGen Inc. announced today that rubitecan, the company's oral anticancer compound that has completed enrollment in Phase III clinical testing as a treatment for pancreatic cancer, will now be called Orathecin(TM), effective immediately. The company also announced today that a replay of the conference call held on Tuesday, March 5th, has been extended until Tuesday, March 12th, at 5 p.m. (Eastern). The replay can be accessed by dialing 800-633-8284 or 858-812-6440 (reservation number 20413545). Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the development and commercialization of products intended to treat life-threatening diseases, particularly cancer. This press release contains 'forward-looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such forward-looking statements include statements regarding our expectations about Orathecin(TM) and other products. The success of such products could differ materially from those projected in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors may include, but are not limited to: risks and uncertainties related to how quickly data can be analyzed to submit an NDA with the FDA, the results of the studies, how lengthy the FDA review process will take, if the application will be accepted, filed and approved or if either drug will ever reach the market. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission, including the reports on Forms 10-K and 10-Q. Contact:
Press Release |
||
 Home | Links | In The News | Clinical Trials Database About Us | FAQ | Research Resources |
||
|
|
||
|
www.pancreatica.org |
||